Fox Run Management’s PAVmed PAVM Stock Holding History

Fox Run Management’s Portfolio PAVM Stock Details PAVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-45	Closed	-$174K	–	646
2021 Q3	$174K	Buy	+45	New	+$142K	0.11%	399

Other funds holding PAVM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Fox Run Management's PAVM Position: Q4 2021 in Review

Fox Run Management sold out of PAVmed (PAVM) in Q4 2021, closing a stake of 45 shares — an estimated $174K sold.

Fox Run Management first reported a position in PAVM in Q3 2021 and held it in 1 quarter. The position peaked at $174K in Q3 2021. 105 funds tracked by Wall St. Rank hold PAVM as of Q4 2021.

Fox Run Management reported no remaining PAVmed position as of Q4 2021 after selling out during the quarter.
Fox Run Management sold 45 PAVmed shares in Q4 2021, an estimated $174K.
Fox Run Management first reported a position in PAVmed in Q3 2021 and held it in 1 quarter.
Fox Run Management's PAVmed position peaked at $174K in Q3 2021.
105 funds tracked by Wall St. Rank held PAVmed as of Q4 2021.

Based on Fox Run Management's 13F filing for Q4 2021, filed 9 Feb 2022.